Related Experiment Video
Updated: Sep 9, 2025
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Insulin resistance in polycystic ovary syndrome: pathophysiological mechanisms of menstrual dysfunction and
Xianrui Chen1, Yu Wan1, Lingling Xie1
1Department of Gynecology, Sichuan Provincial Center for Treatment of Gynecological and Breast Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Purpose:
Polycystic ovary syndrome affects 5-10% of women of reproductive age, with insulin resistance playing a central role in its pathophysiology in up to 80% of cases. This review aims to elucidate the molecular mechanisms by which insulin resistance disrupts ovarian function, contributing to menstrual irregularities and hyperandrogenism. It also evaluates current and emerging therapeutic strategies, with an emphasis on individualized management.
Methods:
A comprehensive review of recent literature was conducted, focusing on molecular studies, clinical trials, and meta-analyses related to insulin signaling pathways in polycystic ovary syndrome, as well as therapeutic interventions. Special attention was paid to ethnic variations, particularly in East Asian populations, and advances in genomic and metabolomic profiling.
Results:
Polycystic ovary syndrome is characterized by selective insulin resistance, wherein metabolic insulin signaling is impaired, but steroidogenic and mitogenic pathways remain responsive, promoting hyperandrogenism and anovulation. East Asian women exhibit significant insulin resistance despite lower body mass index compared with Western populations. Insulin resistance in polycystic ovary syndrome also increases cardiometabolic risks and psychological burden. While lifestyle modification, insulin sensitizers, and hormonal therapy remain first-line treatments, novel approaches such as microbiome-targeted therapies and anti-inflammatory agents show promise.
Conclusion:
Understanding the complex interplay between insulin resistance and ovarian dysfunction is crucial for effective polycystic ovary syndrome management. Integrating emerging molecular insights with digital health tools can facilitate personalized, multidisciplinary approaches that address both reproductive and metabolic aspects of polycystic ovary syndrome, ultimately improving patient outcomes.
Summary Sentence:
This study underscores the pivotal role of insulin resistance in ovarian dysfunction and advocates for integrated, technology-enhanced strategies to personalize PCOS management, thereby improving holistic patient outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:22Diabetes Mellitus: Type 2 and Gestational
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...